Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study

Journal of Urology

Volumn 172, Issue 1, 2004, Pages 90-93

  Antenor, Jo Ann V ^a   Han, Misop ^b   Roehl, Kimberly A ^a   Nadler, Robert B ^b   Catalona, William J ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Mass screening; Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; ARTICLE; BLOOD; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 3242759906     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000132133.10470.bb     Document Type: Conference Paper

References (21)

1. Fang, J., Metter, E. J., Landis, P., Chan, D. W., Morrell, C. H. and Carter, H. B.: Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology, 58: 411, 2001
2. Hakama, M., Stenman, U.-H., Aromaa, A., Leinonen, J., Hakulinen, T. and Knekt, P.: Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland. J Urol, 166: 2189, 2001
3. Gann, P. H., Hennekens, C. H. and Stampfer, M. J.: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA, 273: 289, 1995
4. Catalona, W. J., Smith, D. S. and Ornstein, D. K: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA, 277: 1452, 1997
5. Beahrs, O. H., Henson, D. E. and Hutter, R. V. P.: Prostate cancer staging. In: American Joint Committee on Cancer Staging Manual, 4th ed. Philadelphia: Lippincott, pp. 181-186, 1992
6. Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med, 324: 1156, 1991
7. Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology, 14: 267, 2000
8. Smith, R. A., Cokkinides, V., von Eschenbach, A. C., Levin, B., Cohen, C., Runowicz, C. D. et al: American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin, 52: 8, 2002
9. Stanford, J. L., Stephenson, R. A., Coyle, L. M., Cerhan, J., Correa, R., Eley, J. W. et al: Prostate Cancer Trends 1973-1995, SEER Program. 99-4543. Bethesda: National Cancer Institute, 1999
10. Etzioni, R., Penson, D. F., Legler, J. M., di Tommaso, D., Boer, R., Gann, P. H. et al: Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst, 94: 981, 2002
11. Krumholtz, J. S., Carvalhal, G. F., Ramos, C. G., Smith, D. S., Thorson, P., Yan, Y. et al: Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology, 60: 469, 2002
12. Schatteman, P. H., Hoekx, L., Wyndaele, J. J., Jeuris, W. and Van Marck, E.: Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol, 37: 404, 2000
13. De Marzo, A. M., Marchi, V. L., Epstein, J. I. and Nelson, W. G.: Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol, 155: 1985, 1999
14. Xu, J., Zheng, S. L., Komiya, A., Mychaleckyj, J. C., Isaacs, S. D., Hu, J. J. et al: Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet, 32: 321, 2002
15. Casey, G., Neville, P. J., Plummer, S. J., Xiang, Y., Krumroy, L. M., Klein, E. A. et al: RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet, 32: 581, 2002
16. Cramer, S. D., Chang, B. L., Rao, A., Hawkins, G. A., Zheng, S. L., Wade, W. N. et al: Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst, 95: 1044, 2003
17. Cohen, P., Clemmons, D. R. and Rosenfeld, R. G.: Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res, 10: 297, 2000
18. Swan, J., Breen, N., Coates, R. J., Rimer, B. K. and Lee, N. C.: Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer, 97: 1528, 2003
19. Gohagan, J. K., Prorok, P. C., Hayes, R. B., Kramer, B. S. and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials, 21: 251S, 2000
20. de Koning, H. J., Auvinen, A., Berenguer Sanchez, A., Calais da Silva, F., Ciatto, S., Denis, L. et al: Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer, 97: 237, 2002
21. Carter, H. B., Epstein, J. I., Chan, D. W., Fozard, J. L. and Pearson, J. D.: Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA, 277: 1456, 1997